| Abstrakt: |
A recent study conducted by the Imperial College Healthcare Trust in London aimed to understand the prevalence and risk factors of anxiety and depression in individuals with cutaneous malignant melanoma (CM). The study analyzed data from nine longitudinal and 29 cross-sectional studies, including a total of 7,995 participants. The findings revealed that anxiety and depression were most prevalent during treatment but declined to pre-treatment levels after one year. Women, individuals under 60 years old, and those with a low educational level were more likely to experience anxiety. Additionally, depression rates were higher among advanced-stage patients receiving interferon-a and chemotherapy compared to immune checkpoint inhibition. The study emphasizes the importance of multi-disciplinary vigilance and risk stratification in managing anxiety and depression in CM patients. [Extracted from the article] |
